7-101163253-C-A
Position:
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_003378.4(VGF):c.1591G>T(p.Asp531Tyr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000029 in 1,519,414 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.0000067 ( 0 hom., cov: 29)
Exomes 𝑓: 0.000031 ( 0 hom. )
Consequence
VGF
NM_003378.4 missense
NM_003378.4 missense
Scores
2
6
11
Clinical Significance
Conservation
PhyloP100: 3.18
Genes affected
VGF (HGNC:12684): (VGF nerve growth factor inducible) This gene is specifically expressed in a subpopulation of neuroendocrine cells, and is upregulated by nerve growth factor. The structural organization of this gene is similar to that of the rat gene, and both the translated and the untranslated regions show a high degree of sequence similarity to the rat gene. The encoded secretory protein also shares similarities with the secretogranin/chromogranin family, however, its exact function is not known. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.2380164).
BS2
High AC in GnomAdExome4 at 43 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
VGF | NM_003378.4 | c.1591G>T | p.Asp531Tyr | missense_variant | 2/2 | ENST00000249330.3 | NP_003369.2 | |
VGF | XM_005250561.6 | c.1591G>T | p.Asp531Tyr | missense_variant | 2/2 | XP_005250618.1 | ||
VGF | XM_011516549.4 | c.1591G>T | p.Asp531Tyr | missense_variant | 3/3 | XP_011514851.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
VGF | ENST00000249330.3 | c.1591G>T | p.Asp531Tyr | missense_variant | 2/2 | 1 | NM_003378.4 | ENSP00000249330 | P1 | |
VGF | ENST00000445482.2 | c.1591G>T | p.Asp531Tyr | missense_variant | 2/2 | 5 | ENSP00000400884 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00000669 AC: 1AN: 149586Hom.: 0 Cov.: 29
GnomAD3 genomes
AF:
AC:
1
AN:
149586
Hom.:
Cov.:
29
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000545 AC: 9AN: 165254Hom.: 0 AF XY: 0.0000893 AC XY: 8AN XY: 89558
GnomAD3 exomes
AF:
AC:
9
AN:
165254
Hom.:
AF XY:
AC XY:
8
AN XY:
89558
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000314 AC: 43AN: 1369828Hom.: 0 Cov.: 33 AF XY: 0.0000460 AC XY: 31AN XY: 674268
GnomAD4 exome
AF:
AC:
43
AN:
1369828
Hom.:
Cov.:
33
AF XY:
AC XY:
31
AN XY:
674268
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000669 AC: 1AN: 149586Hom.: 0 Cov.: 29 AF XY: 0.0000137 AC XY: 1AN XY: 72946
GnomAD4 genome
AF:
AC:
1
AN:
149586
Hom.:
Cov.:
29
AF XY:
AC XY:
1
AN XY:
72946
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
ExAC
AF:
AC:
7
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 14, 2023 | The c.1591G>T (p.D531Y) alteration is located in exon 2 (coding exon 1) of the VGF gene. This alteration results from a G to T substitution at nucleotide position 1591, causing the aspartic acid (D) at amino acid position 531 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Benign
T;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Benign
D
LIST_S2
Benign
.;T
M_CAP
Pathogenic
D
MetaRNN
Benign
T;T
MetaSVM
Benign
T
MutationAssessor
Benign
N;N
MutationTaster
Benign
D;D
PrimateAI
Pathogenic
D
PROVEAN
Benign
N;N
REVEL
Benign
Sift
Uncertain
D;D
Sift4G
Uncertain
D;D
Polyphen
D;D
Vest4
MutPred
Gain of phosphorylation at D531 (P = 0.0076);Gain of phosphorylation at D531 (P = 0.0076);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at